Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04260087 · ClinicalTrials.gov registry record
New Daily Persistent Headache Biomarkers Study
A clinical trial, sponsored by Albert Einstein College of Medicine.
- Terminated
- Registry status
- 8
- Enrollment target
NCT04260087 is a clinical trial that was terminated before completion, run by Albert Einstein College of Medicine. The registered enrollment target is 8 participants.
The verdict
NCT04260087 was terminated before completion, sponsored by Albert Einstein College of Medicine.
- TERMINATED
- Registry status
- 8 participants
- Enrollment target
Study Summary
New daily persistent headache is a debilitating syndrome which is seldom researched, poorly understood, and without effective treatments. Chronic migraine is a more common but similarly disabling disorder. The goal of this study is to evaluate the blood levels of two proteins involved with pain signaling; calcitonin gene-related peptide (CGRP) and nerve growth factor (NGF). CGRP levels are known to be elevated in chronic migraine, and recent phase 2 clinical trials suggest that treatments targeting CGRP are safe and effective for treatments for migraine. If CGRP levels are elevated in the blood of people with new daily persistent headache, future studies will be designed to evaluate whether treatments that target CGRP are effective in treating new daily persistent headache. If NGF levels are elevated in the blood of patients with new daily persistent headache and/or chronic migraine, future studies will be designed to evaluate whether treatments that target NGF antibodies (targeted treatments against NGF) are effective in treating NDPH and/or chronic migraine.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2021-11-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04260087
The ClinicalTrials.gov registry entry for NCT04260087 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04260087 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04260087 about?
NCT04260087 is a clinical study titled "New Daily Persistent Headache Biomarkers Study". New daily persistent headache is a debilitating syndrome which is seldom researched, poorly understood, and without effective treatments. Chronic migraine is a more common but similarly disabling disorder. The goal of this study is to evaluate the blood levels of two proteins involved with pain sign...
What is the current status of trial NCT04260087?
This trial is currently terminated. The enrollment target is 8 participants. The study started on 2018-05-01. Estimated completion is 2021-11-18.
Who is sponsoring clinical trial NCT04260087?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.